Meningeal neutrophil infiltration drives inflammation-exacerbated pediatric stroke through IL-36γ signaling

This study reveals that in pediatric stroke, systemic inflammation drives neutrophil infiltration through the meningeal barrier via IL-36γ signaling, establishing the meninges as a critical staging site for immune-mediated brain injury and identifying IL-36γ blockade as a promising therapeutic strategy.

The Gist

The Big Picture: Why Infection Makes Pediatric Strokes Worse

Imagine a child's brain as a highly secure fortress. Usually, this fortress has very strong walls (the blood-brain barrier) that keep the outside world's troublemakers out.

However, the researchers discovered something scary: if a child gets a systemic infection or inflammation (like a bad fever or bacterial infection) before they have a stroke, it's like someone leaving the front gate wide open. This makes the stroke much more damaging than it would be otherwise.

The big question the scientists asked was: How exactly does this happen, and who are the "troublemakers" causing the extra damage?

The Culprits: The "Neutrophil" Soldiers

The immune system has different types of soldiers. Some are heavy tanks (monocytes), and some are fast, aggressive scouts (neutrophils).

In this study, the scientists found that when a child's brain is inflamed and then suffers a stroke, neutrophils are the main villains.

• The Experiment: They used a special model where young mice (representing children) were given a low dose of "inflammation" (LPS) before inducing a stroke.
• The Result: The mice with inflammation had much bigger brain injuries. When the scientists removed the neutrophils, the damage went down. When they removed the other soldiers (monocytes), the damage stayed the same.
• The Takeaway: Neutrophils are the ones driving the extra damage in inflamed pediatric strokes.

The Secret Route: The "Meningeal" Backdoor

For a long time, scientists thought immune cells got into the brain by breaking through the main wall (the blood-brain barrier). But in children, that wall is actually quite tough and doesn't break easily early on.

The researchers discovered a secret backdoor: the meninges.

• The Analogy: Think of the brain as a house. The blood-brain barrier is the front door. The meninges are the roof and the eaves (the space just outside the house).
• What Happened: The scientists watched the neutrophils in real-time. They found that the neutrophils didn't rush through the front door. Instead, they staged a massive gathering on the roof (the meninges) first.
• The Breach: Once enough neutrophils piled up on the roof, they started eating away at the roof tiles (the barrier between the meninges and the brain). Once the roof was breached, they dropped down into the brain's living room (the brain tissue) and started causing chaos.

The Weapon: IL-36γ (The "Alarm Bell")

Once the neutrophils were hanging out on the roof, they started shouting a specific chemical alarm. This alarm is a protein called IL-36γ.

• The Metaphor: Imagine the neutrophils are a gang of vandals. They aren't just breaking in; they are ringing a giant alarm bell (IL-36γ) that wakes up the brain's own security guards (astrocytes and microglia).
• The Effect: When the brain's security guards hear this alarm, they panic and start shouting back, creating a feedback loop of inflammation that makes the brain injury much worse.
• The Discovery: The scientists found that neutrophils arriving via this "roof route" were the ones ringing this specific alarm bell. Neutrophils that came through the front door didn't ring it as loudly.

The Solution: Plugging the Hole and Silencing the Bell

The researchers tested two ways to stop the damage:

1. Silencing the Alarm (IL-36Ra): They injected a "mute button" (an antagonist) directly into the space around the brain (the cisterna magna). This stopped the alarm bell from ringing.
   • Result: The brain injury was significantly smaller.
2. Blocking the Ladder (Anti-ICAM-1): They used a drug to stop the neutrophils from climbing down from the roof into the house.
   • Result: This also reduced the brain injury.

Crucial Note: The scientists tried giving the "ladder blocker" (Anti-ICAM-1) through the bloodstream (systemically) in the past, and it failed in human trials because it messed up the whole body's immune system. But by injecting it locally (right at the roof/brain interface), they could stop the specific bad guys without hurting the rest of the body.

Summary for Everyone

1. Infection + Stroke = Disaster: If a child is sick/inflamed, a stroke hits harder.
2. The Villains: Neutrophils are the main cause of this extra damage.
3. The Secret Path: They don't break the main wall; they gather on the "roof" (meninges) and drop in through a weakened spot.
4. The Trigger: These roof-gathering neutrophils ring a specific chemical alarm (IL-36γ) that makes the brain's own defenses overreact.
5. The Hope: We might be able to treat these strokes by injecting medicine directly around the brain to silence that alarm or block the ladder, rather than giving drugs that affect the whole body.

This study changes how we think about pediatric strokes, suggesting that the "roof" of the brain is a critical place to look for new treatments.

Technical Summary

1. Problem Statement

Pediatric stroke is a devastating condition where infection and systemic inflammation are known major risk factors, yet the underlying immune mechanisms remain poorly understood.

• The Gap: Unlike adult stroke, where blood-brain barrier (BBB) breakdown is the primary driver of immune cell infiltration, pediatric stroke models show minimal early BBB disruption and reduced neutrophil infiltration.
• The Question: How does systemic inflammatory priming (e.g., infection) exacerbate pediatric stroke? What is the route of immune cell entry into the immature brain, and what specific molecular mediators drive this pathology?

2. Methodology

The study utilized a multi-modal approach combining preclinical modeling, advanced imaging, and omics technologies.

• Animal Model: Postnatal Day 16 (P16) C57BL/6J mice (modeling late infancy) subjected to LPS-sensitized photothrombotic stroke (LPS/PT). Mice received a low dose of lipopolysaccharide (LPS) 1 hour prior to photothrombotic middle cerebral artery occlusion (PT) to mimic infection-sensitized stroke.
• Cellular Depletion/Genetic Models:
  • Neutrophil depletion via anti-Ly6G antibodies.
  • Monocyte suppression via Ccr2^RFP/RFP genetic ablation.
• Imaging & Tracing:
  • Two-photon intravital microscopy: Used in GFAP-Cre × ZsGreen reporter mice to visualize the glia limitans and track adoptively transferred, dye-labeled neutrophils in real-time.
  • KikGR Photoconversion: Used to distinguish the origin of infiltrating neutrophils. Meningeal cells were photoconverted from Green to Red at 6 hours post-stroke; subsequent appearance of Red neutrophils in the parenchyma confirmed migration from the meninges rather than the blood.
  • Barrier Permeability Assays: Intracisterna magna (ICM) injection of FITC-dextran and BSA-AF488 to quantify leakage across the meningeal barrier.
• Transcriptomics:
  • Bulk RNA-seq: Sorted neutrophils were distinguished by dual-labeling: Intravenous (IV) anti-CD45 (blood-borne) vs. ICM anti-CD45.2 (meningeal-accessible). Five populations were compared (Blood, IV-Meninges, ICM-Meninges, IV-Brain, ICM-Brain).
  • Single-cell RNA sequencing (scRNA-seq): Performed on sorted CD45+ meningeal immune cells to identify cellular sources of cytokines.
• Therapeutic Intervention: Intracisterna magna (ICM) administration of IL-36 receptor antagonist (IL-36Ra) or anti-ICAM-1 antibody to test therapeutic efficacy.

3. Key Contributions

1. Discovery of a Novel Entry Route: Identified the meningeal barrier (specifically the pia mater and glia limitans) as the primary "staging site" and entry point for neutrophils in pediatric stroke, occurring before significant parenchymal infiltration.
2. Neutrophil Specificity: Demonstrated that inflammation-exacerbated pediatric stroke is driven specifically by neutrophils, not monocytes. Monocyte depletion did not reduce infarct size, whereas neutrophil depletion did.
3. Transcriptional Divergence: Revealed that neutrophils entering via the meningeal route acquire a distinct transcriptional program compared to blood-borne neutrophils, characterized by the upregulation of IL-36γ.
4. Mechanistic Link: Established a feed-forward loop where meningeal neutrophils produce IL-36γ, which signals to glial cells (astrocytes/microglia) to amplify neuroinflammation and barrier dysfunction.
5. Therapeutic Strategy: Validated that local blockade of the meningeal interface (via ICM delivery of IL-36Ra or anti-ICAM-1) reduces infarct volume, whereas systemic delivery of anti-ICAM-1 was ineffective.

4. Key Results

• Pathology: LPS/PT mice exhibited significantly larger infarcts and a massive, hyperactivated neutrophil influx compared to PT-only mice.
• Temporal Dynamics:
  • Neutrophils accumulated in the meninges as early as 6 hours post-stroke.
  • Parenchymal infiltration was delayed until 12–24 hours.
  • Meningeal barrier permeability (measured by tracer leakage) increased by 12 hours, coinciding with neutrophil transmigration across the pia/glia limitans.
• Mechanism of Entry:
  • Imaging showed neutrophils residing on the CSF-facing side of the pia at 6h, then traversing the disrupted glia limitans by 12h.
  • KikGR photoconversion confirmed that a significant fraction of early parenchymal neutrophils originated from the photoconverted meningeal compartment, not the circulating blood.
• Molecular Signature:
  • Bulk RNA-seq of ICM-labeled brain neutrophils (ICM-Brain) showed high enrichment of IL-36γ (Il1f9) compared to blood-derived brain neutrophils (IV-Brain).
  • scRNA-seq confirmed neutrophils as the dominant source of IL-36γ in the meninges of LPS/PT mice.
• Therapeutic Outcomes:
  • IL-36Ra (ICM): Significantly reduced infarct volume, confirming IL-36 signaling drives injury.
  • Anti-ICAM-1 (ICM): Reduced parenchymal neutrophil accumulation and infarct size without affecting meningeal recruitment, proving that blocking the transmigration step across the meningeal barrier is protective.
  • Anti-ICAM-1 (Systemic/IP): Failed to reduce infarct size, highlighting the importance of localized meningeal targeting.

5. Significance

• Paradigm Shift: Challenges the traditional view that BBB breakdown is the sole driver of neuroinflammation in stroke. It highlights the meningeal barrier as a critical, early gatekeeper in pediatric stroke, particularly under inflammatory conditions.
• Developmental Context: Explains why pediatric stroke pathology differs from adults; the immature brain relies on meningeal routes for immune entry when the BBB remains relatively intact early on.
• Therapeutic Implications:
  • Identifies IL-36γ as a novel therapeutic target for inflammation-exacerbated stroke.
  • Suggests that localized delivery (e.g., intracisternal) of immunomodulators targeting the meningeal interface (like anti-ICAM-1) may be effective where systemic therapies have failed (referencing the clinical failure of systemic enlimomab).
  • Provides a potential strategy to limit immune-mediated brain injury in children with concurrent infections or systemic inflammation.